Tuberculosis Control Programs

Tuberculosis (TB) control programs organize the detection, treatment, and prevention of TB across a population, with community and public-health nurses central to case finding, supporting treatment adherence over months of therapy, screening contacts, and managing latent infection. Because TB spreads through the air and requires prolonged treatment, sustained, organized programs rather than isolated treatment are needed to control it.

Definition

A tuberculosis control program is an organized public-health effort to reduce TB transmission and burden through systematic case finding, complete and supported treatment of active disease, contact investigation, screening and treatment of latent infection, and infection control, typically delivered as a national program.

Scope

The topic covers the structure and logic of organized TB control: active and passive case finding, supervised or supported treatment to ensure completion, contact investigation, screening and treatment of latent TB infection, infection control, and the management of drug-resistant disease. It is a reference orientation to TB control as a public-health and nursing domain, not a clinical protocol; it gives no regimens, doses, or individualized advice.

Core questions

• Why does TB require an organized, sustained program rather than treatment of individual cases alone?
• How do the core elements — case finding, supported treatment to completion, contact investigation, and latent-infection management — fit together to interrupt transmission?
• What is the nurse's role across the TB care cascade, from detection through treatment completion?

Key concepts

• Active vs latent tuberculosis infection
• Airborne transmission
• Case finding (active and passive)
• Directly observed and supported treatment
• Treatment adherence and completion
• Contact investigation
• Latent TB infection screening and preventive treatment
• Drug-resistant tuberculosis

Mechanisms

TB control interrupts an airborne transmission cycle that is sustained by infectious cases of pulmonary disease. Finding and treating active cases rapidly renders them non-infectious and prevents onward spread, while ensuring treatment is completed prevents relapse and the emergence of drug resistance — the rationale for supervised or otherwise supported treatment. Contact investigation identifies recently exposed people, a fraction of whom carry latent infection that may later progress to active disease; treating latent infection in those at risk reduces this reservoir of future cases (Sterling, 2020). The probability and timing of progression from latent infection to active disease, which programs must model and target, is itself an area of active study (Menzies, 2018).

Clinical relevance

Community and public-health nurses identify presumptive cases, support adherence across long treatment courses, conduct contact investigations, deliver latent-infection screening and preventive treatment, and apply airborne infection-control measures. Understanding why completion and contact tracing matter helps them sustain programs and reduce resistance. This entry describes the control framework at a reference level and is not a source of diagnostic criteria, regimens, or individualized treatment guidance, which follow current TB guidelines.

Epidemiology

TB remains one of the leading causes of death from a single infectious agent worldwide, with the burden concentrated in low- and middle-income settings and amplified by HIV co-infection and drug resistance. Control depends on the full care cascade — detection, treatment completion, and prevention — and incomplete treatment drives drug-resistant disease, which is harder and costlier to control (Sterling, 2020; WHO End TB Strategy, 2015).

History

TB control evolved from sanatorium isolation in the pre-antibiotic era to effective combination chemotherapy from the mid-twentieth century. The recognition that incomplete treatment bred resistance led to directly observed therapy and the DOTS strategy, later broadened by WHO's Stop TB and End TB strategies, which add latent-infection management, drug-resistant-TB care, and a target of ending the TB epidemic (WHO End TB Strategy, 2015).

Debates

How should treatment adherence be supported?

Directly observed therapy was long the default, but its acceptability and effectiveness versus less restrictive, patient-centred support (including digital adherence technologies) are debated, with the balance between ensuring completion and respecting autonomy and access varying by setting.

Whom to screen and treat for latent infection?

Targeting latent-infection treatment requires estimating who will progress to active disease; uncertainty in progression rates and assumptions in transmission models complicates deciding which groups to prioritize for preventive treatment.

Seminal works

• sterling-2020
• menzies-2018
• who-end-tb-strategy

Frequently asked questions

What is the difference between latent and active tuberculosis?

In latent TB infection the person carries the bacterium but is not ill and is not infectious; in active TB the disease is clinically apparent and, when pulmonary, can be transmitted to others. Control programs both treat active cases and, in selected at-risk people, treat latent infection to prevent future active disease.

Why is completing TB treatment so important?

TB treatment lasts months, and stopping early can allow relapse and the development of drug-resistant strains that are harder to treat; supporting patients to complete the full course is therefore central to control, which is the rationale behind directly observed and other adherence-support approaches.